Oncology as On Today Essence of ESMO WCLC 2022 | Welcome & Introduction

High dimensional Immuno-phenotyping of innmunotherapy response in head and neck cancer

Evaluation of the DNA damage response DDR Network as Predictor of Nivolumab efficany in Head and neck Squamous Cell Carcinoma HNSCC

Molecular targets in Salivary Gland Cancers A Comprehensive genomic analysis of 1666 cases

Role of immunotherapy in TNBC

Traiblazers of Ramiven clinical experience with Abemaciclib in patients with poor prognostic factors

Mutational signature analysis reveals patterns of genomic instability linked to resistance to endocrine therapy

215MO-ICON a randomized phase llb study evaluating chemotherapy combiend with ipilimumab and nivolumab in metastatic hormone receptor positive breast cancer

A randomized phase II trial of metronomic oral vinorelbine plus cyclophosphamide and capecitabine vs wwekly paclitaxel as first or second line treatment in patients with ER Hear2-Metastatic breast cancer MBC

Pooled Exploratory Analysis of Survival in patients with HR Her2 Advanced breast Cancer and Visceral Metastases Treated with Ribociclib Endocrine therapy in the Monaleesa Trials

Tragetting HER2-Low Expression in Breast cancer

Pembrolizumab Plus Olaparib vs Abiraterone or Enzalutamide for Patients with Previously Treated Metastatic Castration-Resistant Prostate Cancer

The Role of Chemotherapy Alongside Hormonal Treatment in mHSPC

Darolutamide in Management of nmCRPC

GC ESMO Guidelines update

Closing Remarks